ClinicalTrials.gg
CompletedNCT03350022Updated Feb 20, 2020

Sham Feeding Post-operative Infants

An interventional study of Sham Feeding in Newborn Morbidity, Oral Aversion and Gastroschisis, sponsored by Le Bonheur Children's Hospital. Completed at 1 site in United States. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by Le Bonheur Children's Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
Up to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 18 studies in Gastroschisis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Gastroschisis · United States.

Enrollment
3rd of 15
102 · median 24
Started
2018
with 3 others
No phase
12 of 18
4 open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Le Bonheur Children's Hospital

Among the 18 studies in Gastroschisis with a site in United States, this one is the 3rd largest by enrollment of the 15 interventional ones, is one of 4 that started in 2018, is one of 12 with no phase, and was the 13th registered.

By phase

18 studies; the count open now beside each. This study's row is marked.

No phasethis study12 · 4 open
Observational3 · 1 open
Phase 11 · 0 open
Phase 2/31 · 0 open
Phase 41 · 0 open

By the year they started

First in 2006; this study’s year is marked. 4 started in 2018.

Size and results

Median enrollment 24 across the 15 interventional studies, 30 across the 3 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 18 studies in Gastroschisis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this pilot study is to evaluate a feeding technique, sham feeding, to promote adequate oral skills in order to prevent oral aversion and/or poor oral skills due to the delay in oral feeds for surgical reasons. Sham feeding is intended for infants who are expected to have a prolonged course without normal enteral feeding by mouth.

Read the detailed description

There is a lack of literature and research on which to base interventions that intend to preserve and develop oral and motor feeding skills in the post-operative patient population during the critical window of opportunity to establish proper oral skills. Due to the lack of positive oral feeding stimuli (i.e. prolonged airway management, nasogastric tubes, and airway and upper GI suctioning), these patients are at risk to develop oral aversions that may negatively impact long-term outcomes.

Parents in the neonatal intensive care unit (NICU) report feelings of stress and loss of control associated with medical interventions. When normal oral feeding is contraindicated, there may be impairment of parent-child bonding and mothers may be less dedicated to providing milk for the infant. Impaired bonding has been shown to affect the parent-child relationship and the child's development long after discharge.

Sham feeding has been shown to be safe and shorten time to oral feeding in infants with esophageal atresia with delayed esophageal repair. Anecdotal evidence from Le Bonheur suggests that sham feeding in post-operative gastroschisis patients improves parental satisfaction and engagement.

There is no literature to describe the use of sham feeding in neonates other than those with esophageal atresia. Anecdotal reports from our institution and others institutions suggests that it increases parental engagement and improves parental satisfaction among patients with other bowel pathology.

This is a cohort study with historical controls within a single level IV NICU. Participants will be offered sham feeding by breast or bottle and observed.

03

Conditions studied

  • Newborn Morbidity
  • Oral Aversion
  • Gastroschisis
  • Bowel Obstruction
  • Short Bowel Syndrome
04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Neonates at least 34 weeks post-menstrual age who have a history of gastrointestinal surgery, require no respiratory support more than 2 lpm by nasal cannula, and have an anticipated prolonged course with to normal oral or enteral feeding. They must have a diagnosis of gastroschisis awaiting return of bowel function, bowel atresia or other obstruction with anticipated feeding contraindication longer than 30 days, or short bowel syndrome intolerant of full intermittent oral feeding.
  2. Mothers of enrolled neonates

Exclusion criteria

Exclusion Criteria:

  1. Lack of consent or parental consent.
  2. to sham feeding as determined by the responsible medical provider.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Sham Feeding

    Procedure: Sham Feeding

Interventions

  • ProcedureSham Feeding

    Sham feeding will be offered to participants.

    Also known as: Observation

06

What researchers measure

Primary outcomes

  1. Time to full feeds

    Time to full oral feeds after resolution of feeding contraindications

    Time frame: 1 year

Secondary outcomes

  1. Growth

    Infant growth parameters

    Time frame: 1 year

  2. Duration of breast feeding

    Duration of breast feeding or pumping of mother's milk

    Time frame: 1 year

  3. Maternal satisfaction

    Maternal satisfaction survey after intervention

    Time frame: 1 year

07

Study locations

1 site
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Sep 2019, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 22, 2017
StartActual
Jan 10, 2018
Primary completionActual
Sep 4, 2019
CompletionActual
Sep 4, 2019
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03350022
Lead sponsor
Le Bonheur Children's Hospital
Responsible party
Mark Weems, MD (Associate Professor of Pediatrics, Le Bonheur Children's Hospital) — Principal investigator
First posted
Nov 22, 2017
Start date
Jan 10, 2018
Primary completion
Sep 4, 2019
Completion
Sep 4, 2019
Last update
Feb 20, 2020

Study contacts

Mark Weems, MD
principal investigator · University of Tennessee

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion